CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 50 enrolled
Drug / intervention
Fentanyl Sublingual Spray +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02597478
NCT02597478Phase 3Completed

A Preliminary Study of Prophylactic Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea

M.D. Anderson Cancer Center·interventional·Posted Nov 5, 2015·Updated Feb 9, 2021

In Brief

A Phase 3 clinical trial evaluating Fentanyl Sublingual Spray, Shuttle Walk Test, and 3 other interventions for Advanced Cancers. Completed, enrolled 50 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to learn if fentanyl can help shortness of breath in cancer patients. Researchers also want to learn if the study drug can help to improve your physical function.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 5, 2015
Enrollment StartJan 4, 2016
Primary CompletionSep 27, 2018
Study CompletionJan 27, 2021
TodayJul 1, 2026
Enrollment to primary: 2.7 yearsPosted 10.7 years ago

Interventions

Fentanyl Sublingual Spraydrug

Low-dose Fentanyl Goup: 15-25% of the morphine equivalent daily dose (MEDD) sprayed into mouth and under tongue one hour after first Shuttle Walk Test. High-Dose Fentanyl Group: 35-45% of the morphine equivalent daily dose (MEDD) sprayed into mouth and under tongue one hour after first Shuttle Walk Test.

Shuttle Walk Testprocedure

Participants walk back and forth between 2 cones in an indoor hallway for up to 12 minutes. After one hour Fentanyl Spray delivered, then second walk test performed.

Questionnairesbehavioral

Questionnaire completed about any breathing problems or other symptoms participant may be having at baseline. End of study questionnaire asks which dose level of study drug participant thinks they received. Participant also completes a questionnaire about how study drug may have helped them and how satisfied they are with the study. It should take about 5 minutes to complete the questionnaire.

Mental Ability Testsbehavioral

After each walk test, participant completes 4 tests of their mental abilities. It should take 15 minutes total to complete these tests.

Phone Callbehavioral

Thirty days study visit participant called by study staff. This call should last about 10 minutes.